Over 4,200 people set to benefit after we recommend daily pill to treat rare chronic kidney disease

23 May 2025 - New treatment sparsentan has been found to slow down the progression of kidney damage, which will change ...

Read more →

Dostarlimab with platinum-based chemotherapy for treating primary advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency

22 May 2025 - Dostarlimab, when used in combination with platinum-based chemotherapy, can be used as an option for the ...

Read more →

New weekly treatment option approved for patients with haemophilia B

21 May 2025 - Final draft guidance published today recommends marstacimab (Hympavzi; Pfizer) for treating severe haemophilia B in patients ...

Read more →

Deal agreed for continued access to life-changing treatment for rare inherited disease

14 May 2025 - NICE is consulting on draft guidance for cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2, ...

Read more →

Health inequalities - an update to NICE’s methods for health technology evaluation

14 May 2025 - Our new modular update focuses on how we consider health inequalities when evaluating technologies for use in ...

Read more →

Erdafitinib for the treatment of patients with unresectable or metastatic urothelial cancer with an FGFR3 alteration after a PD-1 or PD-L1 inhibitor

12 May 2025 - Erdafitinib is recommended as an option for the treatment of adults with unresectable or metastatic urothelial cancer ...

Read more →

Adagrasib for previously treated patients with advanced KRAS G12C mutation positive non-small-cell lung cancer

9 May 2025 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...

Read more →

Osimertinib mesylate in combination with pemetrexed disodium heptahydrate and platinum-based chemotherapy for patients with advanced EGFR mutation positive non-small-cell lung cancer (final guidance)

8 May 2025 - Osimertinib mesylate, when used in combination with pemetrexed disodium heptahydrate and platinum-based chemotherapy, is recommended as an ...

Read more →

Brentuximab vedotin in combination with chemotherapy for the treatment of patients with stage 3 or 4 CD30 positive Hodgkin lymphoma

7 May 2025 - Brentuximab vedotin, when used in combination with doxorubicin hydrochloride, dacarbazine and vinblastine sulphate is recommended as an ...

Read more →

Omaveloxolone for the treatment of patients with Friedreich’s ataxia

6 May 2025 - NICE is unable to make a recommendation on the use of omaveloxolone (Skyclarys) for the treatment of ...

Read more →

Up to 1,000 women a year could benefit from new at-home treatment for endometriosis

1 May 2025 - Our final draft guidance recommends linzagolix (Yselty, Theramex) with hormonal add-back therapy for adults of reproductive age ...

Read more →

Dupilumab for the treatment of patients with moderate to severe chronic obstructive pulmonary disease

24 April 2025 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...

Read more →

The role and value of real-world evidence in health technology decision-making in France, Germany, Italy, Spain, and the UK: insights on external control arms

22 April 2025 - Real-world evidence is increasingly used and accepted by health technology assessment (HTA) bodies as supportive evidence ...

Read more →

Thousands of people a year could benefit from new twice a day tablet for advanced breast cancer

11 April 2025 - We've published final draft guidance recommending capivasertib with fulvestrant, which means the treatment will be funded immediately ...

Read more →

Hundreds of people in England to benefit from take-at-home tablet bladder cancer treatment

10 April 2025 - Today, for the first time, we have given the green light to a targeted treatment for the ...

Read more →